Combination treatment with varenicline and nicotine replacement therapy
Combination treatment with varenicline and nicotine replacement therapy
复制标题
DOI：
10.1093/ntr/ntp042
复制
发表时间：
2009-05-01
影响因子：
4.7
通讯作者：
Hurt, Richard D.
中科院分区：
文献类型：
--
作者：
Ebbert, Jon O.;Burke, Michael V.;Hurt, Richard D.
简介：关于伐尼克兰和尼古丁替代疗法（NRT）联合治疗的安全性和有效性的数据很少：我们回顾了两组参加住宅烟草治疗计划的吸烟者的临床经验：（a）接受伐尼克兰和NRT联合治疗的患者（N = 104）和（B）在伐尼克兰释放前接受治疗的常规护理患者（结果：两组患者的人口学特征相似。在接受伐尼克兰和NRT的吸烟者中，71%使用尼古丁贴片，平均剂量为32 mg/天（SD = 14），73%使用至少两种类型的NRT。在住院计划期间，39%（95% CI = 31%-49%）接受伐尼克兰和NRT的患者和59%（95% CI = 51%-67%）接受常规护理的患者发生了不良事件。共有5名患者（5%）由于不良事件而停用伐尼克兰，而常规治疗组只有1名患者。我们没有观察到伐尼克兰和NRT治疗的患者在6个月时30天点患病率戒烟率的显著差异（54%; 95% CI = 44%-64%）和常规治疗患者（59%; 95% CI = 50%-66%）。我们的研究结果表明，伐尼克兰和NRT的联合治疗是安全的，在居民烟草治疗计划的患者中耐受性良好。
Introduction: A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT).Methods: We reviewed the clinical experience of two groups of cigarette smokers enrolled in a residential tobacco treatment program: (a) patients receiving combination treatment with varenicline and NRT (N = 104) and (b) usual-care patients receiving treatment before the release of varenicline (N = 135).Results: Demographic characteristics were similar between the two groups. Among smokers receiving varenicline and NRT, 71% used the nicotine patch with a mean dose of 32 mg/day (SD = 14) and 73% used at least two types of NRT. Adverse events were experienced by 39% (95% CI = 31%-49%) of patients receiving varenicline and NRT and by 59% (95% CI = 51%-67%) of usual-care patients during the residential program. A total of five patients (5%) discontinued varenicline due to adverse events, compared with one patient in the usual-care group. We did not observe a significant difference in the 30-day point prevalence smoking abstinence rate at 6 months between patients treated with varenicline and NRT (54%; 95% CI = 44%-64%) and usual-care patients (59%; 95% CI = 50%-66%).Discussion: Our findings suggest that combination therapy with varenicline and NRT is safe and well tolerated among patients in a residential tobacco treatment program.